8/26/2014 10:12:22 AM
Please find enclosed the report for the second quarter 2014.
Highlights for second quarter 2014:
• The lead product candidate Betalutin™ has been granted orphan drug designation for treatment of follicular lymphoma in Europe and in the USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by